Amylyx Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Public

  • Employees
  • 384

Employees

  • Stock Symbol
  • AMLX

Stock Symbol

  • Share Price
  • $1.78
  • (As of Thursday Closing)

Amylyx General Information

Description

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.

Contact Information

Website
www.amylyx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
NAS
Corporate Office
  • 43 Thorndike Street
  • Cambridge, MA 02141
  • United States
+1 (617) 000-0000

Amylyx Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Amylyx Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.78 $1.83 $1.70 - $27.00 $121M 68M 3.38M -$1.04

Amylyx Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV (174,624) 643,584 2,292,332
Revenue 398,001 380,786 22,230 0
EBITDA (81,221) 39,230 (201,405) (87,915)
Net Income (71,095) 49,271 (198,375) (87,931)
Total Assets 417,457 517,454 391,453 105,614
Total Debt 3,694 4,237 6,277 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Amylyx Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Amylyx‘s full profile, request access.

Request a free trial

Amylyx Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Amylyx‘s full profile, request access.

Request a free trial

Amylyx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyo
Drug Discovery
Cambridge, MA
384 As of 2023
00000
00000000 00000

000000

reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. E
0000 000000000
Tortola, VI
000 As of 0000
00000
00000000 00000

000000

re dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla
0000000000000
Herlev, Denmark
0 As of 0000
00000
00.000 0000-00-00
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Amylyx Competitors (10)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biohaven Formerly VC-backed Tortola, VI 000 00000 00000000 00000
Orphazyme Formerly VC-backed Herlev, Denmark 0 00000 000000&0
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA 0000 00.000 0000 00.000
Aquinnah Venture Capital-Backed Cambridge, MA 00 0000 0000000000 0000
Cognition Therapeutics Formerly VC-backed New York, NY 00 00000 00000000 00000
You’re viewing 5 of 10 competitors. Get the full list »

Amylyx Patents

Amylyx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240100069-A1 Methods and compositions for treating amyotrophic lateral sclerosis Pending 07-Sep-2022 0000000000
US-20240102018-A1 Oligonucleotide compositions and methods thereof Pending 21-Jul-2022 00000000000
US-20230372263-A1 Methods and compositions for treating amyotrophic lateral sclerosis Pending 17-May-2022 000000000
US-20230364110-A1 Methods and compositions for treating amyotrophic lateral sclerosis Active 12-May-2022 0000000000 0
US-20240102017-A1 Oligonucleotide compositions and methods thereof Pending 10-May-2022 C12N15/1137
To view Amylyx’s complete patent history, request access »

Amylyx Executive Team (13)

Name Title Board Seat Contact Info
Justin Klee Chief Executive Officer & Founder
Joshua Cohen Co-Founder, Co-Chief Executive Officer & Board Member
Linda Arsenault Chief Human Resources Officer
Gina Mazzariello JD General Counsel, Legal & Chief Legal Officer, Legal
Tom Holmes Chief Technical Operations Officer
You’re viewing 5 of 13 executive team members. Get the full list »

Amylyx Board Members (11)

Name Representing Role Since
Alan Walts Ph.D Self Board Observer 000 0000
Daphne Quimi Self Board Member 000 0000
George Milne Ph.D Self Chairman 000 0000
George Milne Ph.D Self Chairman & Board Member 000 0000
Paul Fonteyne Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Amylyx Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Amylyx Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Amylyx‘s full profile, request access.

Request a free trial

Amylyx ESG

Risk Overview

Risk Rating

Updated August, 31, 2023

33.79 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,421

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 928

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 456

Rank

00.00

Percentile

To view Amylyx’s complete esg history, request access »

Amylyx FAQs

  • When was Amylyx founded?

    Amylyx was founded in 2013.

  • Who is the founder of Amylyx?

    Justin Klee and Joshua Cohen are the founders of Amylyx.

  • Who is the CEO of Amylyx?

    Justin Klee and Joshua Cohen are the CEOs of Amylyx.

  • Where is Amylyx headquartered?

    Amylyx is headquartered in Cambridge, MA.

  • What is the size of Amylyx?

    Amylyx has 384 total employees.

  • What industry is Amylyx in?

    Amylyx’s primary industry is Drug Discovery.

  • Is Amylyx a private or public company?

    Amylyx is a Public company.

  • What is Amylyx’s stock symbol?

    The ticker symbol for Amylyx is AMLX.

  • What is the current stock price of Amylyx?

    As of 23-May-2024 the stock price of Amylyx is $1.78.

  • What is the current market cap of Amylyx?

    The current market capitalization of Amylyx is $121M.

  • What is Amylyx’s current revenue?

    The trailing twelve month revenue for Amylyx is $398M.

  • Who are Amylyx’s competitors?

    Biohaven, Orphazyme, Alnylam Pharmaceuticals, Aquinnah, and Cognition Therapeutics are some of the 10 competitors of Amylyx.

  • What is Amylyx’s annual earnings per share (EPS)?

    Amylyx’s EPS for 12 months was -$1.04.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »